ArticleJournal of clinical and translational science2026
Who bears the brunt? Geographic, racial and ethnic disparities in mortality trends of inflammatory bowel disorders in the United States.
Article in Journal of clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), presents increasing global health burdens. Despite advancements in therapy, disparities in mortality trends across demographic and geographic lines persist in the United States. Objective: To analyze IBD-associated mortality trends in the U.S. from 2018 to 2023 using CDC WONDER data, highlighting demographic, regional, and sex-based disparities. Methods: A retrospective analysis of death certificate data from the CDC WONDER database was performed. Age-adjusted mortality rates (AAMRs) were calculated and stratified by sex, race/ethnicity, and region. Trends were evaluated via join-point regression, with the annual percentage change (APC) and average annual percentage change (AAPC) calculated to assess statistical significance. Results: A total of 25,153 IBD-related deaths were recorded. The AAMR increased from 8.269 (2018) to 10.761 (2023), with a notable increase until 2022 (APC: +8.91), followed by a decline in 2023 (APC: -7.55). Men presented higher AAMRs than women did (10.882 vs. 9.838). Non-Hispanic White individuals had the highest AAMR (11.401), whereas Non-Hispanic Black and Asian populations presented the steepest increases (APC: 10.49 and 13.45, respectively). Regionally, the Midwest had the highest AAMR (11.531), with Oregon demonstrating the highest state-level mortality. Conclusions: This study reveals increasing IBD mortality in the U.S., with significant sex, racial, and geographic disparities. These findings highlight systemic inequities in healthcare access, particularly in access to biologic therapy and specialty care. Targeted public health strategies are crucial for reducing disparities and enhancing outcomes in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.